Holen Sie sich die Stockscreener-App
40.13
7.19%
-3.11
Handel nachbörslich:
40.11
-0.02
-0.05%
Schlusskurs vom Vortag:
$43.24
Offen:
$42.86
24-Stunden-Volumen:
834.70K
Relative Volume:
1.12
Marktkapitalisierung:
$2.33B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.5326
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-6.85%
1M Leistung:
-0.91%
6M Leistung:
+33.32%
1J Leistung:
-10.56%
1-Tages-Spanne:
$39.96
$44.10
1-Wochen-Bereich:
$39.96
$44.10
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
40.13 | 2.52B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Q3 2025 HighlightsAgios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones - Seeking Alpha
How supply chain issues affect Agios Pharmaceuticals Inc. stockWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Will Agios Pharmaceuticals Inc. stock see PE expansion2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com
Will Agios Pharmaceuticals Inc. benefit from macro trendsWeekly Volume Report & Real-Time Volume Trigger Notifications - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsRecession Risk & Safe Capital Investment Plans - newser.com
Agios (AGIO) Unveils Promising Mitapivat Data at ASH 2025 - GuruFocus
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - The Manila Times
What data driven models say about Agios Pharmaceuticals Inc.’s futureQuarterly Trade Summary & Daily Entry Point Alerts - newser.com
Agios (Nasdaq: AGIO) shows mitapivat data: 77.8% alpha-thal response; 30.5-week mean - Stock Titan
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROEShare Buyback & AI Powered Market Entry Ideas - newser.com
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com
Is Agios Pharmaceuticals Inc. building a consolidation basePortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
What earnings revisions data tells us about Agios Pharmaceuticals Inc.Entry Point & Smart Investment Allocation Insights - newser.com
Can Agios Pharmaceuticals Inc. stock reach $100 price targetWeekly Trade Review & Reliable Trade Execution Plans - newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc.Inflation Watch & Breakout Confirmation Alerts - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flows2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
What drives Agios Pharmaceuticals Inc stock priceMarket Capitalization Trends & High Return Capital Strategies - earlytimes.in
Is Agios Pharmaceuticals Inc. (8AP) stock among top earnings playsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Institutional scanner results for Agios Pharmaceuticals Inc.Bond Market & Weekly Chart Analysis and Trade Guides - newser.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Savvy Advisors Inc. Takes Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Published on: 2025-11-02 02:45:06 - newser.com
Candlestick signals on Agios Pharmaceuticals Inc. stock todayQuarterly Market Summary & Reliable Price Action Trade Plans - newser.com
Agios Pharmaceuticals Q3 2025 Earnings Preview - MSN
Agios outlines Q4 2025 PYRUKYND milestones and anticipates U.S. thalassemia approval amid global expansion - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Keeps Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Published on: 2025-11-01 04:26:21 - newser.com
Agios Pharmaceuticals’ Earnings Call: Growth and Challenges - MSN
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues - sharewise.com
Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):